Name | 5-(2-Furyl)-N-[3-(1H-imidazol-1-yl)propyl]-1,2-oxazole-3-carboxamide |
---|---|
Synonyms |
5-(2-Furyl)-N-[3-(1H-imidazol-1-yl)propyl]-1,2-oxazole-3-carboxamide
3-Isoxazolecarboxamide, 5-(2-furanyl)-N-[3-(1H-imidazol-1-yl)propyl]- SKL2001 |
Description | SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. |
---|---|
Related Catalog | |
Target |
Wnt/β-catenin[1] |
In Vitro | SKL2001 is an agonist of the Wnt/β-catenin pathway, and also upregulates the expression of Axin2, a downstream target of the Wnt/β-catenin pathway, but shows no effect on NF-κB, p53 reporter activity and GSK-3β activity. SKL2001 causes osteoblast differentiation (20 and 40 μM) and suppresses preadipocyte differentiation (5, 10, and 30 μM) via the activation of the Wnt/β-catenin pathway. SKL2001 (5, 10, and 30 μM) stabilizes intracellular β-catenin in 3T3-L1 cells[1]. SKL2001 (40 μM) significantly inhibits the proliferation of HCT116 spheroids independently of cytotoxicity and the inhibition is reversible; SKL2001 cuases cell cycle arrest in HCT116 spheroids. SKL2001 (40 μM) enhances round-shape spheroid formation and E-cadherin expression[2]. |
Cell Assay | ST2 cells are cultured on glass chamber slides and then treated with DMSO or SKL2001 for 15 h. After treatment, the cells are washed with PBS, fixed with 4% formaldehyde, permeabilized in 0.3% Triton X-100, and blocked in 4% bovine serum albumin for 1 h. The cells are stained with anti-β-catenin antibody and then analyzed by confocal microscopy using a microscope[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 595.7±50.0 °C at 760 mmHg |
Molecular Formula | C14H14N4O3 |
Molecular Weight | 286.286 |
Flash Point | 314.1±30.1 °C |
Exact Mass | 286.106598 |
LogP | 0.37 |
Vapour Pressure | 0.0±1.7 mmHg at 25°C |
Index of Refraction | 1.655 |
Storage condition | -20℃ |